Skip to main content

Job Opportunity: FDA Postdoctoral Research Fellowship in Nanotechnology, FDA/NCTR, Jefferson AR

Posted by on Monday, August 10, 2020 in Job Opportunities.

*Applications will be reviewed on a rolling-basis.

One research opportunity is currently available with the Office of the Commissioner (OC) Office of Women’s Health (OWH), U.S. Food and Drug Administration (FDA). The project will be located at the National Center for Toxicological Research (NCTR), Nanotechnology Core Facility located in Jefferson, Arkansas.

The major focus of the project is to conduct innovative research through in vitro studies to investigate sex-based differences in the immune response to nanomaterial. The participant will have the opportunity to conduct research and learn in vitro immunotoxicological techniques such as cell culture techniques, ELISA, immunohistochemistry, microscopy and flowcytometry. This research will also include the opportunity to learn different physico-chemical characterization techniques and approaches using the instruments available at the Nanotechnology Core Facility.

Under the guidance of a mentor, the selected participant will have the opportunity to perform experiments and analyze experimental data, maintain records of lab research, and coordinate the research flow with the project’s collaborators. The participant will be able to present the research at internal and external meetings and publish the findings in peer-reviewed journals.

Anticipated Appointment Start Date: September 1, 2020

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Jefferson, Arkansas, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA.  OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency.  This agreement covers such topics as the following:

  • Non-employee nature of the ORISE appointment;
  • Prohibition on ORISE Fellows performing inherently governmental functions;
  • Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
  • The fact that research materials and laboratory notebooks are the property of the FDA;
  • ORISE fellow’s obligation to protect and not to further disclose or use non-public information.

Qualifications

The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by August 31, 2020. Degree must have been received within five years of the appointment start date.

Preferred skills:

  • Experience in immunology, toxicology, pharmacology, biochemistry and biology
  • Prior experience with nanotechnology
  • Previous graduate experience or familiarity with in vitro immunological techniques or fields of science
  • Demonstrated written and oral communication skills

Degree: Doctoral Degree received within the last 60 months or anticipated to be received by 8/31/2020 11:59:00 PM.

 

For more information and to apply https://www.zintellect.com/Opportunity/Details/FDA-OWH-2020-0012

Tags: